Mutations of p53 in cancer can result in a gain of function associated with tumour progression and metastasis. We show that inducible expression of several p53 'hotspot' mutants promote a range of centrosome abnormalities, including centrosome amplification, increased centrosome size and loss of cohesion, which lead to mitotic defects and multinucleation. These mutant p53-expressing cells also show a change in morphology and enhanced invasive capabilities. Consequently, we sought for a means to specifically target the function of mutant p53 in cancer cells. This study has identified ANKRD11 as a key regulator of the oncogenic potential of mutant p53. Loss of ANKRD11 expression with p53 mutation defines breast cancer patients with poor prognosis. ANKRD11 alleviates the mitotic defects driven by mutant p53 and suppresses mutant p53-mediated mesenchymal-like transformation and invasion. Mechanistically, we show that ANKRD11 restores a native conformation to the mutant p53 protein and causes dissociation of the mutant p53-p63 complex. This represents the first evidence of an endogenous protein with the capacity to suppress the oncogenic properties of mutant p53.
Introduction
The p53 protein is a tumour suppressor that predominantly functions as a sequence-specific transcription factor regulating the expression of various target genes involved in cell-cycle arrest, apoptosis, senescence, DNA repair, and inhibition of angiogenesis and metastasis, in response to a variety of cellular insults (Lane, 1992; Liu and Chen, 2006) . Approximately 50% of all human cancers contain a mutation in the TP53 gene (Hollstein et al., 1991; Vogelstein et al., 2000) , with the majority of these mutations occurring within the DNA-binding domain (Bullock and Fersht, 2001; Olivier et al., 2010) . Mutations at six specific residues in the DNAbinding domain have been identified as mutational 'hotspots' and are classified into two categories: DNA contact mutants (R248Q, R248W, R273C and R273H) involving residues, which specifically interact with DNA, and structural mutants (R175H, G245S, R249S and R282W), which show local or global distortions of the p53 protein structure (Cho et al., 1994) .
Mutant p53 proteins show both loss-and gain-offunction (GOF) characteristics. Loss of function is largely due to the inability of mutant p53 to bind to the canonical wild-type p53-binding site, resulting in an inability to transactivate its target genes (Kato et al., 2003; Scian et al., 2004) , an attenuated tumoursuppressive function and, consequently, deregulated cellular growth and apoptosis. By contrast, GOF characteristics of mutant p53 are critical for tumour progression and metastasis (Brosh and Rotter, 2009; Oren and Rotter, 2010) . A variety of GOF phenotypes of mutant p53 have been reported, including increased invasive and metastatic potential of cells, resistance to chemotherapies, regulation of pro-inflammatory and anti-apoptotic pathways, and increased genomic instability (Oren and Rotter, 2010) , all of which give mutant p53-expressing cells a selective growth and survival advantage.
Various strategies have been developed to target mutant p53 in cancers, including small molecules that aim to restore the native conformation to the unfolded mutant p53 proteins (Bykov et al., 2002) , or target their interactions with family members (Di Agostino et al., 2008; Kravchenko et al., 2008) . Using a novel proteinbased approach, we have shown previously that ANKRD11 can restore normal transactivation potential to a p53 hotspot mutant in a breast cancer cell line (Neilsen et al., 2008) , and represents the first endogenously expressed protein with a capacity to rescue mutant p53 function. In this study we used a panel of ecdysoneinducible cell lines in a p53-null background to express various p53 hotspot mutants to investigate cellular processes that are driven by mutant p53 GOF and which can be suppressed by ANKRD11.
Results p53 mutation and loss of ANKRD11 expression define cancer patients with poor prognosis Previously, we established that ANKRD11 could restore normal transactivation potential to the p53-R273H mutant (Neilsen et al., 2008) and thus we explored a wider role for ANKRD11 in the suppression of the oncogenic functions of mutant p53. ANKRD11 was robustly expressed in the normal breast epithelium, however was downregulated in the majority of breast tumours ( Figure 1a) . Analysis of the expression profiling of a cohort of breast tumours (Miller et al., 2005) revealed that the combination of p53 mutation and loss of ANKRD11 expression defined a subset of patients with poor outcomes (Figure 1b ). Low ANKRD11 expression was also significantly associated with poor survival in cohorts of bladder and lung tumours (Supplementary Figure S1 ). Furthermore, loss of ANKRD11 expression was significantly associated with invasion to the lymph nodes in breast tumours expressing mutant ANKRD11 suppresses mutant p53 gain of function JE Noll et al p53 ( Figure 1c) . Collectively, the data support a role for ANKRD11 as a suppressor of the oncogenic potential of mutant p53. We subsequently sought to understand the mechanism of this suppression.
Mutant p53 drives centrosome abnormalities and multinucleation, which can be suppressed by ANKRD11 Several biological pathways were examined to assess mutant p53 GOF. These assays were based on the inducible expression of mutant p53 in the H1299 p53-null genetic background. In these cell lines, p53 can be expressed dose dependently to the inducing agent, Ponasterone-A (PonA). Furthermore, inducible expression of wild-type p53 was equivalent to the DNA damage-induced activation of the p53 pathway and mutant p53 levels comparable to endogenous mutant p53 expression in cancer cell lines (Supplementary Figure S2) .
Induction of mutant p53 in H1299 cells resulted in a time-dependent increase in multinucleation, with approximately 25% of cells showing more than one nuclei after 96 h of mutant p53 expression (Figure 2a) . Giant multinucleated H1299 cells were observed after prolonged expression of mutant p53 (Supplementary Figure S3A) . Co-staining cells for a-tubulin and g-tubulin, Mutant p53 expression promotes multinucleation and centrosome abnormalities, which are suppressed by ANKRD11. EI p53-WT, EI p53-R248W, EI p53-R175H, EI p53-R249S and EI p53-R175H-ANKRD11 were plated at 10% confluence and treated with 2.5 mg/ml PonA for 0, 24, 48, 72 or 96 h. Multinucleation and centrosome characteristics were subsequently analysed. g-Tubulin was used as a centrosome marker for centrosome measurements. The error bars represent the s.e.m. of three independent experiments. *Po0.05; **Po0.01; and ***Po0.001. (a) The percentage of multinucleated cells was determined 4 0 ,6-diamidino-2-phenylindole (DAPI) and a-tubulin staining. For each experiment 100 cells were counted per condition. (b) The average number of centrosomes per cell was determined in wild-type and p53 mutants at 24-h intervals over 96 h. For each experiment 40 cells were counted per condition. (c) The average centrosome size was determined in wild-type and p53 mutants at 24-h intervals over 96 h. For each experiment 40 cells were counted per condition. Where two or more centrosomes were present, the largest centrosome was measured. (d) The average distance between centrosomes was determined in wild-type and p53 mutants at 24-h intervals over 96 h. For each experiment 40 cells were counted per condition. Where three or more centrosomes were present, the largest distance between two neighbouring centrosomes was measured. (e) The level of wild-type or p53-R175H protein expression after 24 h of induction in the presence or absence of ANKRD11 re-expression was determined by western blot analysis, with b-actin protein levels used as a loading control. markers for microtubules and centrosomes, respectively, showed that induction of mutant p53 was associated with a small but significant increase in the number of centrosomes per cell (Figure 2b ). The limited extent of the increase was most likely due to the small number of cell cycles observed. Centrin immunofluorescence studies demonstrated that these aberrant centrosomal frequencies were not due to centriole splitting (Supplementary Figure S3B ). However, there was a significant increase in average centrosome size (Figure 2c) , which was not due to increased g-tubulin expression (Supplementary Figure S3B ). A significant increase in the average distance between centrosomes was also observed (Figure 2d ). These observations are demonstrated as bone fide mutant p53 GOF pathways as multinucleation and centrosomal aberrations were not observed in cells with induced wild-type p53 , and importantly multinucleation of EI-H1299 cells was not observed after treatment with PonA (Supplementary Figure S4) . Furthermore, at 24 h after induction cells were observed with centrosomal amplification without multinucleation, suggesting that the defects in centrosomal duplication are driving the multinucleation phenotype and not mitotic failure.
To examine how the restored expression of ANKRD11 would impact upon the ability of mutant p53 to disrupt normal mitotic fidelity, ANKRD11 was stably expressed in EI p53 mutant cells (which show undetectable ANKRD11 expression) to approximate physiological levels, as judged by the levels observed in primary epithelial cells (Supplementary Figure S5) . Restoring ANKRD11 expression completely abolished the ability of induced p53-R175H to drive multinucleation in EI p53-R175H cells (Figure 2a) . A similar result was also seen after induction of p53-R248W in the presence of ANKRD11 expression (Supplementary Figure S6) . Furthermore, induction of p53-R175H failed to modulate centrosome size, separation or cohesion in the presence of restored ANKRD11 expression (Figures 2b-d) . Importantly, ANKRD11 did not influence p53-R175H mutant protein levels after exposure to the inducing agent PonA (Figure 2e ). Together these findings illustrate the capacity of ANKRD11 to suppress the oncogenic potential of a p53 GOF mutant.
Mutant p53 expression is associated with chromosome segregation defects that can be suppressed by ANKRD11 As centrosome abnormalities have previously been linked to aberrant mitotic progression (Mailand et al., 2002; Wonsey and Follettie, 2005) , we next examined the ability of mutant p53-expressing cells to undergo mitosis. The defects in centrosome duplication and segregation in the induced mutant p53 cells was associated with a 20-30% increase in the frequency of abnormal mitotic spindles (Figures 3a and b) , and a significant increase in cells with lagging chromosomes ( Figure 3c ) and anaphase bridges (Figure 3d ), compared with un-induced cells. The duration of mitosis, as assessed by live-cell imaging, showed that mutant p53 cells slowed the progression through mitosis to 72-75 min (Po0.03) as compared with 57-58 min in un-induced H1299 cells ( Figure 3e and Supplementary Movies S1-S6). These findings show that mutant p53 expression does impact upon the normal execution of mitosis.
In the presence of restored ANKRD11 expression, the ability of induced p53-R175H to drive the formation of abnormal spindles, lagging chromosomes and anaphase bridges was completely ablated (Figures 3a-d) . Furthermore, the induced EI p53-R175H cells expressing ANKRD11 showed an average of 60 min in mitosis as compared with 75 min for induced p53-R175H alone ( Figure 3e and Supplementary Movies S7 and S8). These observations indicate that p53 mutants cannot drive tumourigenesis in the presence of physiological levels of ANKRD11.
Mutant p53 induces a mesenchymal morphology that is suppressed by ANKRD11
Gene expression arrays were used to determine the specific genes and pathways regulated upon induction of the p53-R175H mutant (Table 1 ). After analysis of microarray expression data, Ingenuity Pathway Analysis revealed that many of the genes regulated by p53-R175H were shared across multiple biological pathways, which converged towards a network involved in cell motility and cell-to-cell signalling/interaction (Table 1 and Supplementary Figure S7 ). Consequently, we investigated whether induction of mutant p53 affected the colony formation and morphology of epithelial H1299 cells. Control H1299 cells grew from single cells as tight colonies with defined boundaries, typical of epithelial cells (Figure 4a , left). Upon induction of a structural (R175H) or DNA contact (R248Q) mutant, cells acquired an elongated mesenchymal-like morphology and showed disordered growth and decreased colony density (Figure 4a , middle). In addition, ZO-1 immunofluorescence of EI p53-R175H cells showed that cells dissociated from each other within 16 h of p53-R175H induction (Figure 4b ), which is indicative of an invasive phenotype.
As we had already shown that ANKRD11 could alleviate the mitotic defects caused by mutant p53 induction, we next aimed to determine whether the mesenchymal-like morphology of mutant p53-expressing cells could also be suppressed by ANKRD11. Physiological ANKRD11 expression in EI p53-R175H cells suppressed the mesenchymal-like phenotype, as demonstrated by retention of tight colony formation after p53-R175H induction (Figure 4a , right, and Figure 4b ). Stable ANKRD11 expression in EI p53-R248Q cells also resulted in a restoration of the epithelial-like phenotype (Figure 4a , right).
ANKRD11 suppresses mutant p53 invasive GOF
Mutant p53 GOF has a key role in tumour progression, particularly through migration, invasion and metastasis. As induction of p53-R175H gave rise to an invasive phenotype, we aimed to determine whether this was associated with an increased invasive capacity.
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The ability of un-induced or induced cells to invade through matrigel towards a chemo-attractant was measured in real-time by using an Xcelligence system. Induction of p53-R175H did indeed result in an enhanced invasive capacity of H1299 cells, as demonstrated by a 2.5-fold (Po0.05) increased rate of invasion ( Figure 5 ). Stable expression of ANKRD11 in this system also ablated the ability of the induced R175H mutant to drive invasion ( Figure 5 ). Importantly, we also demonstrate that ANKRD11 can influence the tumorigenic properties of an additional mutant p53-expressing cancer cell line, MDA-MB-468 (p53 R273H). Expression of ANKRD11 in this cell line was shown to slow the rate of migration of the MDA-MB-468 breast cancer cell line in a mutant p53-dependent manner (Supplementary Figure S8) . The average percentage of anaphase/telophase cells with lagging chromosomes was determined by using DAPI as a marker of the DNA. (d) The average percentage of daughter (newly divided) cells with anaphase bridges was determined by using DAPI as a marker of the DNA. (e) The average time taken for cells to undergo mitosis. Synchronized cells were followed by time-lapse microscopy and imaged every5 min. Time in mitosis was defined as the time from nuclear envelope breakdown until the point at which two daughter cells could be seen. For each experiment 50 cells were counted per condition.
ANKRD11 suppresses mutant p53 gain of function JE Noll et al ANKRD11 restores a wild-type conformation and function to the p53-R175H mutant protein We speculate that ANKRD11 can restore normal p53 function to p53 mutants as a consequence of its ability to directly interact with mutant p53 proteins and revert the protein to a wild-type p53 conformation. We have previously shown the ankyrin repeat domain (ANKRD11 144-288 aa ) to directly interact with wild-type p53 (Neilsen et al., 2008) . We confirmed through co-immunoprecipitation assays that ANKRD11 144-288 aa could interact with both wild-type and eight p53 hotspot mutants (Figure 6a ). Further to these findings, we identified the C-terminus of p53 (p53 325-393 aa ) as the minimal region required for interaction with the ankyrin domain of ANKRD11 (Supplementary Figure S9) .
To test the ability of ANKRD11 to affect the mutant p53 tertiary structure, we used the conformation-specific p53 antibody PAb1620, which recognizes the wildtype p53 native protein structure under non-denaturing conditions (Milner et al., 1987) . In the presence of ANKRD11, induced p53-R175H showed enhanced binding to the PAb1620 antibody, in comparison with that observed in the absence of ANKRD11 (Figure 6b ). These data suggest that association of ANKRD11 with p53-R175H restores the mutant protein conformation to more closely resemble the wild-type protein, thus facilitating recognition by the PAb1620 antibody. This newly adopted 'wild-type' conformation of the mutant p53 protein was also associated with restoration of p53 target gene expression by the p53 mutant to a level similar to that achievable by wild-type p53 (Supplementary Figure S10) . This restoration of transcriptional activity to the mutant p53 protein is also accompanied by a reduction in the percentage of cells undergoing mitosis, as demonstrated by MPM2 staining. Induction of wild-type p53 leads to a 65% reduction in cells undergoing mitosis (Po0.01), which is not seen after induction of various mutant p53 proteins. However, in the presence of ANKRD11, induction of the p53-R175H mutant leads to a significant (Po0.01) reduction in the number of cells in mitosis (Supplementary Figure S11 ).
ANKRD11 impedes mutant p53-p63 and mutant p53-p73 complex formation Previous studies have established that wild-type p53 does not interact with p63 and p73, whereas p53 mutants, including R175H, R249S and R273H, show GOF interactions with p63 and p73 (Strano et al., 2000 (Strano et al., , 2002 Gaiddon et al., 2001) . Immunoprecipitation in H1299 cells of co-transfected TAp63 and p53 mutants, including the eight p53 hotspot mutants, encompassing both DNA contact (R248Q, R248W, R273C and R273H) and structural (R175H, G245S, R249S, R282W) mutants suggests that p63 was primarily sequestered by p53 structural mutants (Figure 7a ). The DNA contact mutant p53-R273H also weakly coprecipitated with p63, which is consistent with previously published reports, whereas the remaining three DNA contact mutants did not interact (Figure 7a) . The same subset of p53 mutants that interacted with p63 were also shown to form a complex with TAp73 ( Figure 7b ). As the interaction between mutant p53 and p63 contributes to the invasive GOF of mutant p53 in H1299 cells (Muller et al., 2009) , we speculated that the suppressive functions of ANKRD11 are due, in part, to an interference with mutant p53-p63 complex formation.
Immunoprecipitation results demonstrated the formation of an R175H-p63 complex in the absence of ANKRD11 (Figure 7c, lane-7) . However, expression of the complete ankyrin domain (ANKRD11 144-288 aa ) resulted in dissociation of the R175H-p63 complex by up to 62% (Figure 7c, lane-8 ). ANKRD11 144-288 aa was also co-expressed with p53-R175H and p73 in the same system, and the interaction between R175H and p73 was reduced to 56% of the baseline (Figure 7d ). These results indicate that the association of ANKRD11 with mutant p53 disrupts its ability to interact with both p63 and p73. Further immunoprecipitation experiments using various regions encompassing the five ankyrin repeats present in ANKRD11 defined the region of the domain that disrupts the mutant p53-p63 interaction. Ankyrin repeats 1-3 dissociated the p53-R175H-p63 complex by approximately 54% (Figure 7c, lane-9) . The R175H-p63 interaction was, however, maintained in the presence of ankyrin repeats 4 and 5 (Figure 7c, lane-10) . Expression of the first ankyrin repeat did not dissociate the R175H-p63 complex; however, expression of repeats The EI p53-R175H cell line were seeded at single-cell density and allowed to develop into colonies for 72 h prior to addition of PonA (2.5 mg/ml) as indicated. Colonies were stained for the presence of cell-cell junctions, as indicated by ZO-1 staining (red).
2 and 3 resulted in a 21% decrease in the observed interaction between p53-R175H and p63 (Supplementary Figure S12 ). It was therefore inferred that an 80-amino-acid region of ANKRD11 (ANKRD11 144-288 aa ) dissociated the R175H-p63 complex, with a slight reduction in complex formation also observed after coexpression of a 50-amino-acid region (ANKRD11 176-225 aa ). These results are summarized in Figure 7e .
Discussion
Our current understanding of the GOF properties of mutant p53 is largely based on studies involving stable expression of p53 mutants in a p53-null background (Dong et al., 2009; Muller et al., 2009) or mutant p53-knock-in transgenic animal models (Song et al., 2007) . These systems have proven useful to functionally characterize the persistent, long-term oncogenic properties of mutant p53 such as invasion, metastasis and largescale genetic abnormalities. However, using the ecdysoneinducible system, we have been able to directly investigate the primary pathways that are initiated by mutant p53 expression and which ultimately lead to its GOF, as well as identify ANKRD11 as an endogenously expressed protein capable of suppressing mutant p53 GOF.
Knockdown of endogenous mutant p53 in MDA-MB-468 cells results in reduced metastasis in a mouse model (Adorno et al., 2009) . Expression of ANKRD11 in MDA-MB-468 cells also significantly reduced their ability to form colonies on plastic (Neilsen et al., 2008) . Furthermore, loss of ANKRD11 expression with p53 mutation defines breast cancer patients with invasive tumours and poor prognosis (Figure 1 ). Low ANKRD11 expression is also correlated with poor 5-year survival in bladder and lung cancer patients (Supplementary Figure S1) . Loss of heterozygosity of chromosome 16q24 (the genomic location of the ANKRD11 gene) is associated with good prognosis in breast cancer patients (Hansen et al., 1998) ; therefore, the observation that there was a trend for higher survival in the wild-type p53-expressing breast tumours with low ANKRD11 expression may be an artefact of the loss of the 16q genomic region and not specific to ANKRD11. The correlation between low ANKRD11 expression and poor survival in mutant p53-expressing breast tumours supports a role for ANKRD11 as a suppressor of the oncogenic potential of mutant p53. Using the ecdysoneinducible system, we established three biological assays for investigating mutant p53 GOF and the effect of ANKRD11 on these processes. Specifically we investigated mitotic defects arising from centrosome abnormalities, cellular morphology changes and invasion.
Using these approaches, we show that inducible expression of three p53 'hotspot' mutants results in multinucleation, centrosome aberrations and a significant increase in the percentage of cells with abnormal spindles (Figures 2 and 3) . Previous studies link aberrant centrosomes to both defective mitosis (Mailand et al., 2002) and multinucleation (Wonsey and Follettie, 2005) , both of which we show to occur after mutant p53 induction. The increased distance observed between centrosomes in mutant p53-expressing cells may be due 
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WB: α-p53 (R175H) Figure 6 ANKRD11 restores a native conformation to a p53 mutant.
(a) H1299 cells were sequentially transfected with 4 mg of FLAG-ANKRD11 144-288 aa and 0.5 mg of wild-type or mutant p53 expression constructs, followed by immunoprecipitation using an anti-FLAG antibody. Inputs and immunoprecipitated complexes were subjected to western blot analysis using anti-p53 and anti-FLAG antibodies. All p53 mutants investigated are shown to co-precipitate with ANKRD11 144-288 aa above the level of the non-specific, background levels seen in the empty vector control lanes. (b) EI p53-R175H and EI p53-R175H-ANKRD11 cells were treated with 2.5 mg/ml PonA for 24 h, immunoprecipitated with the indicated antibody and detected by western blot analysis using an anti-p53 (DO-1) and anti-mouse light chain-specific secondary antibody.
to de-regulation of b-catenin as wild-type p53 inhibits bcatenin, with high b-catenin levels associated with mutant p53 expression and centrosome splitting (Sadot et al., 2001; Hadjihannas et al., 2010) .
Our findings are consistent with observations of mutant p53 GOF in mouse models where expression of the mouse R172H mutant (equivalent to human R175H) results in tumours showing centrosome amplification and an associated aneuploidy (Murphy et al., 2000; Hingorani et al., 2005; Caulin et al., 2007) . However, these previous reports are confounded as they use a K-Ras G12D mutation as an initiating oncogenic event (Hingorani et al., 2005; Caulin et al., 2007) . Our data show that mutant p53 alone is sufficient to drive the observed GOF phenotype. These mitotic defects would provide a likely origin for chromosomal instability, a common feature of many human tumours, which promotes metastases and is correlated with poor patient prognosis (Kuukasjarvi et al., 1997; Rajagopalan and Lengauer, 2004 ).
This study has uncovered several novel genes and biological processes regulated by mutant p53, which regulate cellular movement and cell-to-cell signalling and interaction (Table 1 ). R175H has previously been shown to reprogramme the cellular transcriptome through recruitment to novel target genes by various transcription factors such as NF-Y (Di Agostino et al., 2006) , VDR (Stambolsky et al., 2010) and nuclear factor-kb (Schneider et al., 2010) . Indeed, our pathway analysis also showed that the nuclear factor-kb-signalling pathway was strongly upregulated upon induced expression of p53-R175H (Supplementary Figure S5B) , further confirming a role for nuclear factor-kb in the GOF of mutant p53 (Weisz et al., 2007) . Interestingly, several integrins (ITGA3 and ITGB3) were also upregulated upon induction of p53-R175H, consistent with a previously observed role for integrin recycling in the oncogenic GOF of mutant p53 (Muller et al., 2009 Figure 7 The ankyrin domain of ANKRD11 dissociates the p53-R175H-p63/p73 complexes. (a) H1299 cells were co-transfected with 2 mg of wild-type or mutant p53 expression constructs and 4 mg of HA-p63. Cellular extracts were subjected to immunoprecipitation using an anti-p53 (DO-1) antibody. Inputs and immunoprecipitates were subjected to western blot analysis using anti-p53 and anti-HA antibodies. (b) Cells were treated as described above (panel a) but p53 was co-transfected with HA-p73. (c) H1299 cells were sequentially transfected with 2 mg of p53-R175H, 4 mg of HA-p63 and 2 mg of various Myc-ANKRD11 fragment expression constructs, as indicated, followed by immunoprecipitation using an anti-p53 (DO-1) antibody. Inputs and immunoprecipitates were subjected to western blot analysis using anti-p53, anti-Myc and anti-HA antibodies. The amount of p63 co-precipitated with p53-R175H was determined by densitometry. (d) Cells were treated as above (panel c) but with HA-p73 and Myc-ANKRD11 144-28 8aa expression constructs. (e) A schematic diagram illustrating the region of ANKRD11 capable of dissociating the mutant p53-p63 complex.
mesenchymal-like phenotype after treatment with transforming growth factor-b (Adorno et al., 2009) . We observe this morphological change upon induction of both structural (R175H) and DNA contact (R248Q) p53 mutants, with no additional treatment (Figure 4a ). Variations in cell density may account for this contradiction to previous data, as cells plated at higher densities did not show this phenotype after mutant p53 induction (data not shown).
Mutant p53 GOF activity results in enhanced cellular migration, invasion and metastasis. We demonstrate that stable expression of ANKRD11 in the EI p53-R175H cell line can suppress mutant p53-dependent invasion ( Figure 5 ). Furthermore, ANKRD11 is demonstrated to reduce the rate of migration of the MDA-MB-468 breast cancer cell line, expressing the endogenous p53-R273H mutant, in a mutant p53-dependent manner (Supplementary Figure S8) . Silencing of mutant p53 expression has no effect on cell migration, which is consistent with previous reports showing that silencing of endogenous mutant p53 expression alone does not alter cellular migration in the MDA-MB-231 breast cancer cell line (Adorno et al., 2009 ). However, expression of wild-type p53 has been demonstrated to inhibit cell migration (Gadea et al., 2002; Roger et al., 2006) . Therefore, the observation that stable ANKRD11 expression can decrease the rate of cell migration in a mutant p53-dependent manner is likely due to a restoration of wild-type-like activity to the endogenous p53 mutant, as described previously (Neilsen et al., 2008) .
For each of the assays described, expression of ANKRD11 with induced mutant p53 restores the cellular phenotype to that seen in the un-induced state, that is, ANKRD11 suppresses the GOF of mutant p53. We have also established that ANKRD11 can restore wild-type p53 activity to p53 mutants. These data represent the first reported evidence of an endogenously expressed protein that has the capacity to suppress mutant p53 GOF as well as restore transcriptional activity to a p53 mutant (Neilsen et al., 2008) . This has broad implications for the development of new cancer therapies designed to target this pathway, as these may result not only in suppression of the invasive and metastatic properties of mutant p53 tumours, but also prevent tumour growth through restoration of wild-type p53 activity.
We propose that ANKRD11 suppresses mutant p53 GOF by directly interacting with mutant p53 proteins, resulting in a native wild-type p53 conformation ( Figure 6 ). This unique property of ANKRD11 is similar to that reported for the small molecules and peptides, PRIMA-1 (Bykov et al., 2002) and CDB-3 (Friedler et al., 2002; Issaeva et al., 2003) , which reportedly restore a native conformation to mutant p53. We also show that expression of the ANKRD11 ankyrin domain is sufficient to dissociate the p53-R175H Á p63 and p53-R175H Á p73 complexes (Figure 7) . The ability of mutant p53 to drive tumourigenesis is reported to be partially based on its ability to sequester the p63 and p73 proteins, thus disrupting their function to suppress metastasis (Di Como et al., 1999; Gaiddon et al., 2001) . It is likely that ANKRD11 is suppressing mutant p53 GOF through an interaction with the C-terminus of p53 (Supplementary Figure S9) , coupled with its ability to enhance the acetylation of the DNAbinding domain (Neilsen et al., 2008) , thus leading to a stabilized, active conformation of p53 and subsequent dissociation of the mutant p53 Á p63/p73 complexes. Alternatively, the C-terminus of p53 has been shown to be required for mutant p53 invasive activity (Muller et al., 2009) ; therefore, we speculate that ANKRD11 may be outcompeting the recruitment of another unknown oncogenic protein required for mutant p53 GOF.
Studies defining mutant p53 interactions with p63 and p73 have included different subsets of mutants, with predominant focus on p53-R175H and p53-R273H (Strano et al., 2000 (Strano et al., , 2002 Gaiddon et al., 2001) . In this study we present a comprehensive comparison of the interaction of eight p53 hotspot mutants with p63 and p73. All four p53 mutants classed as structural preferentially interact with both p63 and p73, while only R273H of the four p53 DNA contact mutants interact with p63 and p73 (Figure 7) , consistent with previous studies (Gaiddon et al., 2001; Strano et al., 2002) . A previously reported interaction between p63 and R248W (Gaiddon et al., 2001) was not observed in this study. These data and others suggest a correlation between the structural integrity of the p53 protein and its ability to interact with p63/p73 (Gaiddon et al., 2001) . Interestingly, the endogenous p53-R273H mutant is reported to be immunoprecipitated from cell lines using the mutant-specific antibody, PAb240 (Muller et al., 2008) , suggesting that p53-R273H shows some structural perturbations. Furthermore, no interaction with p63 or p73 was observed for p53-R273C, suggesting that the amino acid at codon 273 has an integral role in this interaction. In contrast to other structural mutants, G245S did not interact with p63 or p73 (Figure 7) . However, the p53-G245S protein is only locally distorted in comparison with p53-R175H and p53-R282W, which are distorted globally (Wong et al., 1999; Brosh and Rotter, 2009 ). These findings suggest that the extent of mutant p53 protein distortion may also dictate its ability to sequester p63 and p73.
The DNA contact mutants R248W and R248Q are shown to have a GOF in relation to multinucleation (Figure 2a ) and cellular morphology (Figure 4a ), respectively; however, these mutants did not interact with p63 or p73. Therefore these mutants acquire their GOF independently of p63 or p73, presumably through interactions with other regulatory proteins. Possible candidates include the DNA-repair complex protein, MRE11. The specific interaction between MRE11 and the R248W mutant is reported to inactivate ATM, thereby inducing genetic instability (Song et al., 2007; Liu et al., 2010) .
This study provides novel insight into the complex oncogenic processes that are driven by mutant p53. The discovery of ANKRD11 as an endogenously expressed protein with the capacity to suppress various mutant p53 functions as well as restore wild-type activity to p53 mutants opens a novel avenue to indirectly restore tumour-suppressor activity to the guardian of the genome.
Materials and methods
Cell lines and antibodies H1299, MDA-MB-231, MCF-7 and SK-BR-3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) or RPMI with 10% fetal calf serum. Ecdysone-inducible derivatives of the H1299 cells were generated by stable transfection of pVgRXR and selection in zeocin (Invitrogen, Carlsbad, CA, USA) at 100 mg/ml, followed by stable transfection of the pI-TK-Hygro-p53-wt/mut plasmid linearized using XbaI and subsequent selection of clones in hygromycin-B (Sigma Aldrich, St Louis, MO, USA) at 600 mg/ml. Stable cell lines expressing GFP-ANKRD11-Myc were generated through retroviral transduction using the pLNCX2 vector, as described previously (Neilsen et al., 2008) , and selection in G418 (Invitrogen) at 500 mg/ml. The antibodies used were: mouse anti-Myc, mouse anti-FLAG, mouse anti-p53 DO-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); rat anti-haemagutinin (HA) (Roche, Dee Why, NSW, Australia); rabbit anti-b-tubulin (Abcam, Cambridge, MA, USA); mouse anti-b-actin (Sigma Aldrich); mouse anti-p21 (Thermo Fisher Scientific, Scoresby, VIC, Australia); mouse anti-ZO-1 (Zymed, San Francisco, CA, USA); mouse anti-centrin, rabbit anti-g-tubulin (Sigma, Aldrich); mouse anti-MPM2 (Millipore, Billerica, MA, USA); anti-mouse IgG horseradish peroxidase (HRP)-linked, antirabbit IgG HRP-linked (GE Healthcare, Rydalmere, NSW, Australia); anti-rat IgG HRP-linked (Dako, Carpentaria, CA, USA); mouse light chain-specific HRP-linked (Millipore).
Plasmids
To generate epitope-tagged fragments of ANKRD11, specific regions of ANKRD11 were PCR-amplified using primers 1-8 (Supplementary Table S1 ) from pLNCX2-ANKRD11-Myc (Neilsen et al., 2008) and cloned in-frame into mammalian the expression vector pCMV-Tag2 or pCMV-Myc. Myc-p53-FL was generated as described previously (Neilsen et al., 2008) . Specific fragments of p53 were PCR-amplified using primers 9-14 (Supplementary Table S1 ) and cloned in-frame into pCMVMyc. Deletion constructs of Myc-p53 were generated through overlap PCR using primers 15-19 (Supplementary Table S1 ).
Breast tumour analysis, expression microarray analysis and realtime reverse transcription-PCR Breast tumour patient samples were prepared and real-time PCR was performed are as described previously (Kumar et al., 2005; Pishas et al., 2011) . Expression profiling was performed by using the Affymetrix Human Gene 1.0 ST array as per the manufacturer's protocol.
Co-immunoprecipitation assays H1299 cells (5 Â 10 5 ) were seeded into 60-mm dishes and transfected with the indicated constructs using Lipofectamine 2000 (Invitrogen). For the interaction domain-mapping studies, cells were collected 24 h after transfection, resuspended in lysis buffer 1 (50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Triton X-100) supplemented with 1 Â complete protease inhibitor cocktail (Roche), sonicated and centrifuged. Clarified lysates were incubated with FLAG-M2 agarose (Sigma) for 2 h at 4 1C with rotation. Beads were washed twice with lysis buffer-1, twice with wash buffer (50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate) and twice with 20 mM Tris-HCl (pH 7.5). Protein complexes were eluted with the FLAG peptide (200 ng/ml). For the p63/p73 interaction studies, cells were sequentially transfected with the indicated plasmids and harvested 48 h after transfection in 300 ml of lysis buffer-2 (20 mM Tris-HCl (pH 8), 1 mM EDTA, 0.5% NP-40, 150 mM NaCl, 1 mM DTT, 10% glycerol), sonicated and centrifuged. Clarified lysates were incubated with 200 ng of anti-p53 (DO-1) for 1 h at 4 1C with rotation, followed by addition of 10 ml of protein-G-sepharose beads (GE Healthcare) for 1 h. Beads were washed four times with 400 ml of lysis buffer-2 and protein complexes were eluted with 1 Â sodium dodecyl sulphate loading buffer at 95 1C for 5 min. Western blot analysis of inputs and co-immunoprecipitated protein complexes was performed as described previously (Kumar et al., 2005) .
Centrosome defects and multinucleation assays
To measure centrosome defects, unsynchronized cells were plated at 10% confluence and treated with 2.5 mg/ml PonA for the indicated time periods. Multinucleation, number of centrosomes and centrosome size were measured in interphase cells. Distance between centrosomes was measured in S and G 2 cells. Fifty cells were counted per condition. For mitotic assays, cells were plated at 10% confluence, synchronized by double thymidine block and harvested at 11 h after release. PonA at 2.5 mg/ml was added 24 h before harvesting. Hundred cells were counted per condition.
Colony development assays EI p53-mut cell lines were treated with or without 2.5 mg/ml PonA for 72 h. Cells were subsequently collected and plated in duplicate in a six-well format at a density of 1000 cells per well in DMEM±PonA. Cells were grown for 10 days, fixed for 5 min with methanol and stained with Giemsa Stain (Sigma Aldrich) as per the manufacturer's protocol.
Immunofluorescence
For ZO-1 staining, 2000 cells were plated on glass coverslips in a six-well and allowed to form small colonies of 4-6 cells (B2 days). PonA was added to the wells at a final concentration of 2.5 mg/ml for 0, 16 or 40 h. The immunofluorescence protocols were based on those previously described (Neilsen et al., 2008) .
For mitotic staining, cells were synchronized by addition of 2.5 mM thymidine for 16 h then washed three times in phosphate-buffered saline (PBS). The cells were incubated for a further 10 h before the thymidine block was repeated. Cells were fixed with ice-cold methanol at 11 h after release from the second thymidine block. PonA was added at 24 h prior to harvesting. Where metaphase cells were required 10 mM MG132 was added at 2 h prior to harvesting. Cells were blocked in 3% bovine serum albumin (BSA) in PBS for 20 min, followed by incubation with the indicated antibodies in 03% BSA/PBS solution (30 min, room temperature) and incubation with the indicated Alexa-Fluor-conjugated secondary antibodies (30 min, room temperature). Coverslips were mounted in Mowiol containing 2.5% DABCO. Cells were visualized using a DeltaVision personal DV deconvolution microscope (GE Healthcare). Images underwent restoration deconvolution and were analysed by using softWoRx version 3.6.1. Fluorescent images represent projections of z-stacks. Images were cropped and resized using Adobe Photoshop (San Jose, CA, USA).
Invasion assays
Real-time invasion assays were performed by using the xCelligence Real-Time Cell Analyzer DP (Roche), as per the manufacturer's protocol. Ecdysone-inducible H1299 derivatives, EI-H1299-p53-R175H or EI-H1299-p53-R175H-ANKRD11 were grown in the presence or absence of PonA at 2.5 mg/ml for 24 h. After induction, sub-confluent cell cultures were collected in serum-free media and plated at 2 Â 10 4 cells per well in the top chamber of a CIM-16 plate pre-coated with 5%
